<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02920970</url>
  </required_header>
  <id_info>
    <org_study_id>EX-MKTG-71 (C16-601)</org_study_id>
    <nct_id>NCT02920970</nct_id>
  </id_info>
  <brief_title>The Clinical Comparison of Narafilcon A and Stenfilcon A Contact Lenses</brief_title>
  <official_title>The Clinical Comparison of Narafilcon A and Stenfilcon A Contact Lenses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coopervision, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coopervision, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare the clinical performance and subjective acceptance of the
      narafilcon A lens with the stenfilcon A lens when used on a daily wear, daily disposable
      basis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomized, subject-masked, crossover, bilateral study, controlled by cross
      comparison. Seventy subjects will use each lens type for a week in a random sequence.
      Follow-up visits for each lens will be performed after one week of wear. Lenses will be worn
      on a daily wear, daily disposable wear schedule.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2016</start_date>
  <completion_date type="Actual">May 31, 2017</completion_date>
  <primary_completion_date type="Actual">December 22, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular Physiology</measure>
    <time_frame>1 week</time_frame>
    <description>Ocular physiology assessment of narafilcon A and stenfilcon A lenses by biomicroscopy (Scale 0-4, 0.25 steps, 0=normal, 4=severe).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>1 week</time_frame>
    <description>Visual acuity for narafilcon A and stenfilcon A are assessed by LogMAR. High contrast is measured with black letters on a white background. Low contrast is measured with gray letters on a white background.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comfort Level of Stenfilcon A and Narafilcon A Lenses</measure>
    <time_frame>1 week</time_frame>
    <description>Subjective responses for overall comfort will be evaluated for each pair using questionnaire (Scale 0-100, 0=causes pain, cannot be tolerated, 100=excellent, cannot be felt).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dryness of Stenfilcon A and Narafilcon A Lenses</measure>
    <time_frame>1 week</time_frame>
    <description>Subjective responses for dryness will be evaluated for each pair using questionnaire (Scale 0-100, 0=extremely poor, high levels of dryness, 100=excellent, no dryness).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vision of Stenfilcon A and Narafilcon A Lenses</measure>
    <time_frame>1 week</time_frame>
    <description>Subjective responses for vision will be evaluated for each pair using questionnaire (Scale 0-100, 0=unacceptable, lens cannot be worn, 100=excellent).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lens Surface - Deposition on Stenfilcon A and Narafilcon A Lenses</measure>
    <time_frame>1 week</time_frame>
    <description>Lens surface for narafilcon A and stenfilcon A is assessed. (Grades 0-4, 0=normal, 1=trace, 2=mild, 3=moderate, 4=severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lens Surface - Wettability of Stenfilcon A and Narafilcon A Lenses</measure>
    <time_frame>1 week</time_frame>
    <description>Lens wettability for narafilcon A and stenfilcon A is assessed. (Grades 0-4, 0=normal, 1=trace, 2=mild, 3=moderate, 4=severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lens Fit - Horizontal Centration of Stenfilcon A and Narafilcon A Lenses</measure>
    <time_frame>1 week</time_frame>
    <description>Horizontal centration assessed for narafilcon A and stenfilcon A lenses categorized as extremely nasal, slightly nasal, optimum, slightly temporal, extremely nasal.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lens Fit - Vertical Centration of Stenfilcon A and Narafilcon A Lenses</measure>
    <time_frame>1 week</time_frame>
    <description>Vertical centration assessed for narafilcon A and stenfilcon A lenses and graded as extremely nasal, slightly nasal, optimum, slightly temporal, extremely temporal.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lens Fit - Corneal Coverage of Stenfilcon A and Narafilcon A Lenses</measure>
    <time_frame>1 week</time_frame>
    <description>Corneal coverage will be assessed for narafilcon A and stenfilcon A and categorized as extremely inadequate, slightly inadequate, optimum, slightly excessive, extremely excessive.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lens Movement</measure>
    <time_frame>1 week</time_frame>
    <description>Lens movement assessed for narafilcon A and senofilcon A lenses and categorized as extremely inadequate, slightly inadequate, optimum, slightly excessive, extremely excessive.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>narafilcon A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants are randomized to wear narafilcon A lens pair for one week during the cross over study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>stenfilcon A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants are randomized to wear stenfilcon A lens pair for one week during the cross over study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>narafilcon A</intervention_name>
    <description>contact lens</description>
    <arm_group_label>narafilcon A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>stenfilcon A</intervention_name>
    <description>contact lens</description>
    <arm_group_label>stenfilcon A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects will only be eligible for the study if:

               1. They are of legal age (18) and capacity to volunteer.

               2. They understand their rights as a research subject and are willing and able to
                  sign a Statement of Informed Consent.

               3. They are willing and able to follow the protocol.

               4. They agree not to participate in other clinical research for the duration of this
                  study.

               5. They have a contact lens spherical prescription between -1.00 to - 6.00D
                  (Diopters) (inclusive)

               6. They have a spectacle cylindrical correction of -0.75D or less in each eye.

               7. They can be satisfactorily fitted with the study lens types.

               8. At dispensing, they can attain at least 0.10 logMAR distance high contrast visual
                  acuity in each eye with the study lenses within the available power range.

               9. They currently use soft contact lenses or have done so in the previous six
                  months.

              10. They are willing to comply with the wear schedule (at least six days per week and
                  for at least eight hours per day).

              11. They own a wearable pair of spectacles.

        Exclusion Criteria:

          -  Subjects will not be eligible to take part in the study if:

               1. They have an ocular disorder which would normally contra-indicate contact lens
                  wear.

               2. They have a systemic disorder which would normally contra-indicate contact lens
                  wear.

               3. They are using any topical medication such as eye drops or ointment.

               4. They have had cataract surgery.

               5. They have had corneal refractive surgery.

               6. They have any corneal distortion resulting from previous hard or rigid lens wear
                  or have keratoconus.

               7. They are pregnant or breast-feeding.

               8. They have any ocular abnormality which would, in the opinion of the investigator,
                  normally contraindicate contact lens wear.

               9. They have any infectious disease which would, in the opinion of the investigator,
                  contraindicate contact lens wear or pose a risk to study personnel; or they have
                  any immunosuppressive disease (e.g. HIV), or a history of anaphylaxis or severe
                  allergic reaction.

              10. They have taken part in any other contact lens or care solution clinical trial or
                  research, within two weeks prior to starting this study.

              11. They currently wear either the stenfilcon A lens or narafilcon A lens.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Morgan, PhD, FAAO, FBCLA</last_name>
    <role>Study Director</role>
    <affiliation>Eurolens Research, University of Manchester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eurolens Research - The University of Manchester</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9PL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>September 29, 2016</study_first_submitted>
  <study_first_submitted_qc>September 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2016</study_first_posted>
  <results_first_submitted>October 9, 2017</results_first_submitted>
  <results_first_submitted_qc>July 26, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 16, 2019</results_first_posted>
  <last_update_submitted>July 26, 2018</last_update_submitted>
  <last_update_submitted_qc>July 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>There were 72 participants were enrolled in the study, of which 70 were dispensed a contact lens to wear and 2 failed screening.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Stenfilcon A First Then Narafilcon A</title>
          <description>Participants are randomized to wear stenfilcon A lens first for one week then narafilcon A.</description>
        </group>
        <group group_id="P2">
          <title>Narafilcon A First Then Stenfilcon A</title>
          <description>Participants are randomized to wear narafilcon A lens first for one week then stenfilcon A.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Poor Lens Fit</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Number of Baseline Participants</title>
          <description>Total number of participants enrolled in the study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.8" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ocular Physiology</title>
        <description>Ocular physiology assessment of narafilcon A and stenfilcon A lenses by biomicroscopy (Scale 0-4, 0.25 steps, 0=normal, 4=severe).</description>
        <time_frame>1 week</time_frame>
        <population>There were 2 participants excluded from the analysis for narafilcon A due to protocol deviations</population>
        <group_list>
          <group group_id="O1">
            <title>Stenfilcon A</title>
            <description>Participants are randomized to wear stenfilcon A lens pair for one week during the cross over study.</description>
          </group>
          <group group_id="O2">
            <title>Narafilcon A</title>
            <description>Participants are randomized to wear narafilcon A lens pair for one week during the cross over study.</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Physiology</title>
          <description>Ocular physiology assessment of narafilcon A and stenfilcon A lenses by biomicroscopy (Scale 0-4, 0.25 steps, 0=normal, 4=severe).</description>
          <population>There were 2 participants excluded from the analysis for narafilcon A due to protocol deviations</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Conjuctival hyperaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" spread="0.25"/>
                    <measurement group_id="O2" value="0.76" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limbal hyperaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="0.28"/>
                    <measurement group_id="O2" value="0.62" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Corneal vascularisation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.14"/>
                    <measurement group_id="O2" value="0.03" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Microcysts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oedema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Corneal staining</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" spread="0.41"/>
                    <measurement group_id="O2" value="0.33" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conjuctival staining</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57" spread="0.49"/>
                    <measurement group_id="O2" value="0.76" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Papillary conjuctivitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" spread="0.35"/>
                    <measurement group_id="O2" value="1.00" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Visual Acuity</title>
        <description>Visual acuity for narafilcon A and stenfilcon A are assessed by LogMAR. High contrast is measured with black letters on a white background. Low contrast is measured with gray letters on a white background.</description>
        <time_frame>1 week</time_frame>
        <population>There were 2 participants excluded from the analysis for narafilcon A at follow up due to protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Stenfilcon A</title>
            <description>Participants are randomized to wear stenfilcon A lens pair and assessed after one week during the cross over study.</description>
          </group>
          <group group_id="O2">
            <title>Narafilcon A</title>
            <description>Participants are randomized to wear narafilcon A lens pair and assessed after one week during the cross over study.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Acuity</title>
          <description>Visual acuity for narafilcon A and stenfilcon A are assessed by LogMAR. High contrast is measured with black letters on a white background. Low contrast is measured with gray letters on a white background.</description>
          <population>There were 2 participants excluded from the analysis for narafilcon A at follow up due to protocol deviations.</population>
          <units>LogMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>High Contrast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" spread="0.07"/>
                    <measurement group_id="O2" value="-0.10" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Contrast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.09"/>
                    <measurement group_id="O2" value="0.17" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comfort Level of Stenfilcon A and Narafilcon A Lenses</title>
        <description>Subjective responses for overall comfort will be evaluated for each pair using questionnaire (Scale 0-100, 0=causes pain, cannot be tolerated, 100=excellent, cannot be felt).</description>
        <time_frame>1 week</time_frame>
        <population>There were 2 participants excluded from the analysis for narafilcon A at 1 week due to protocol deviations</population>
        <group_list>
          <group group_id="O1">
            <title>Stenfilcon A</title>
            <description>Participants are randomized to wear stenfilcon A lens pair and assessed after one week during the cross over study.</description>
          </group>
          <group group_id="O2">
            <title>Narafilcon A</title>
            <description>Participants are randomized to wear narafilcon A lens pair and assessed after one week during the cross over study.</description>
          </group>
        </group_list>
        <measure>
          <title>Comfort Level of Stenfilcon A and Narafilcon A Lenses</title>
          <description>Subjective responses for overall comfort will be evaluated for each pair using questionnaire (Scale 0-100, 0=causes pain, cannot be tolerated, 100=excellent, cannot be felt).</description>
          <population>There were 2 participants excluded from the analysis for narafilcon A at 1 week due to protocol deviations</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.4" spread="9.8"/>
                    <measurement group_id="O2" value="83.1" spread="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dryness of Stenfilcon A and Narafilcon A Lenses</title>
        <description>Subjective responses for dryness will be evaluated for each pair using questionnaire (Scale 0-100, 0=extremely poor, high levels of dryness, 100=excellent, no dryness).</description>
        <time_frame>1 week</time_frame>
        <population>There were 2 participants excluded from the analysis for narafilcon A due to protocol deviations</population>
        <group_list>
          <group group_id="O1">
            <title>Stenfilcon A</title>
            <description>Participants are randomized to wear stenfilcon A lens pair and assessed after one week during the cross over study.</description>
          </group>
          <group group_id="O2">
            <title>Narafilcon A</title>
            <description>Participants are randomized to wear narafilcon A lens pair and assessed after one week during the cross over study.</description>
          </group>
        </group_list>
        <measure>
          <title>Dryness of Stenfilcon A and Narafilcon A Lenses</title>
          <description>Subjective responses for dryness will be evaluated for each pair using questionnaire (Scale 0-100, 0=extremely poor, high levels of dryness, 100=excellent, no dryness).</description>
          <population>There were 2 participants excluded from the analysis for narafilcon A due to protocol deviations</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.1" spread="17.2"/>
                    <measurement group_id="O2" value="81.2" spread="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vision of Stenfilcon A and Narafilcon A Lenses</title>
        <description>Subjective responses for vision will be evaluated for each pair using questionnaire (Scale 0-100, 0=unacceptable, lens cannot be worn, 100=excellent).</description>
        <time_frame>1 week</time_frame>
        <population>There were 2 participants excluded from the analysis for narafilcon A at 1 week due to protocol deviations</population>
        <group_list>
          <group group_id="O1">
            <title>Stenfilcon A</title>
            <description>Participants are randomized to wear stenfilcon A lens pair and assessed after one week during the cross over study.</description>
          </group>
          <group group_id="O2">
            <title>Narafilcon A</title>
            <description>Participants are randomized to wear narafilcon A lens pair and assessed after one week during the cross over study.</description>
          </group>
        </group_list>
        <measure>
          <title>Vision of Stenfilcon A and Narafilcon A Lenses</title>
          <description>Subjective responses for vision will be evaluated for each pair using questionnaire (Scale 0-100, 0=unacceptable, lens cannot be worn, 100=excellent).</description>
          <population>There were 2 participants excluded from the analysis for narafilcon A at 1 week due to protocol deviations</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.4" spread="9.4"/>
                    <measurement group_id="O2" value="88.4" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lens Surface - Deposition on Stenfilcon A and Narafilcon A Lenses</title>
        <description>Lens surface for narafilcon A and stenfilcon A is assessed. (Grades 0-4, 0=normal, 1=trace, 2=mild, 3=moderate, 4=severe)</description>
        <time_frame>1 week</time_frame>
        <population>There were 2 participants excluded from the analysis for narafilcon A at 1 week due to protocol deviations</population>
        <group_list>
          <group group_id="O1">
            <title>Stenfilcon A</title>
            <description>Participants are randomized to wear stenfilcon A lens pair and assessed after one week during the cross over study.</description>
          </group>
          <group group_id="O2">
            <title>Narafilcon A</title>
            <description>Participants are randomized to wear narafilcon A lens pair and assessed after one week during the cross over study.</description>
          </group>
        </group_list>
        <measure>
          <title>Lens Surface - Deposition on Stenfilcon A and Narafilcon A Lenses</title>
          <description>Lens surface for narafilcon A and stenfilcon A is assessed. (Grades 0-4, 0=normal, 1=trace, 2=mild, 3=moderate, 4=severe)</description>
          <population>There were 2 participants excluded from the analysis for narafilcon A at 1 week due to protocol deviations</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lens Surface - Wettability of Stenfilcon A and Narafilcon A Lenses</title>
        <description>Lens wettability for narafilcon A and stenfilcon A is assessed. (Grades 0-4, 0=normal, 1=trace, 2=mild, 3=moderate, 4=severe)</description>
        <time_frame>1 week</time_frame>
        <population>There were 2 participants excluded from the analysis for narafilcon A at 1 week due to protocol deviations</population>
        <group_list>
          <group group_id="O1">
            <title>Stenfilcon A</title>
            <description>Participants are randomized to wear stenfilcon A lens pair and assessed after one week during the cross over study.</description>
          </group>
          <group group_id="O2">
            <title>Narafilcon A</title>
            <description>Participants are randomized to wear narafilcon A lens pair and assessed after one week during the cross over study.</description>
          </group>
        </group_list>
        <measure>
          <title>Lens Surface - Wettability of Stenfilcon A and Narafilcon A Lenses</title>
          <description>Lens wettability for narafilcon A and stenfilcon A is assessed. (Grades 0-4, 0=normal, 1=trace, 2=mild, 3=moderate, 4=severe)</description>
          <population>There were 2 participants excluded from the analysis for narafilcon A at 1 week due to protocol deviations</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lens Fit - Horizontal Centration of Stenfilcon A and Narafilcon A Lenses</title>
        <description>Horizontal centration assessed for narafilcon A and stenfilcon A lenses categorized as extremely nasal, slightly nasal, optimum, slightly temporal, extremely nasal.</description>
        <time_frame>1 week</time_frame>
        <population>There were 2 participants excluded from the analysis for narafilcon A at 1 week due to protocol deviations</population>
        <group_list>
          <group group_id="O1">
            <title>Stenfilcon A</title>
            <description>Participants are randomized to wear stenfilcon A lens pair and assessed after one week during the cross over study.</description>
          </group>
          <group group_id="O2">
            <title>Narafilcon A</title>
            <description>Participants are randomized to wear narafilcon A lens pair and assessed after one week during the cross over study.</description>
          </group>
        </group_list>
        <measure>
          <title>Lens Fit - Horizontal Centration of Stenfilcon A and Narafilcon A Lenses</title>
          <description>Horizontal centration assessed for narafilcon A and stenfilcon A lenses categorized as extremely nasal, slightly nasal, optimum, slightly temporal, extremely nasal.</description>
          <population>There were 2 participants excluded from the analysis for narafilcon A at 1 week due to protocol deviations</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Extremely Nasal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slightly Nasal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Optimum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slightly Temporal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely Temporal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lens Fit - Vertical Centration of Stenfilcon A and Narafilcon A Lenses</title>
        <description>Vertical centration assessed for narafilcon A and stenfilcon A lenses and graded as extremely nasal, slightly nasal, optimum, slightly temporal, extremely temporal.</description>
        <time_frame>1 week</time_frame>
        <population>There were 2 participants excluded from the analysis for narafilcon A at 1 week due to protocol deviations</population>
        <group_list>
          <group group_id="O1">
            <title>Stenfilcon A</title>
            <description>Participants are randomized to wear stenfilcon A lens pair and assessed after one week during the cross over study.</description>
          </group>
          <group group_id="O2">
            <title>Narafilcon A</title>
            <description>Participants are randomized to wear narafilcon A lens pair and assessed after one week during the cross over study.</description>
          </group>
        </group_list>
        <measure>
          <title>Lens Fit - Vertical Centration of Stenfilcon A and Narafilcon A Lenses</title>
          <description>Vertical centration assessed for narafilcon A and stenfilcon A lenses and graded as extremely nasal, slightly nasal, optimum, slightly temporal, extremely temporal.</description>
          <population>There were 2 participants excluded from the analysis for narafilcon A at 1 week due to protocol deviations</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Extremely inferior</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slightly inferior</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Optimum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slightly superior</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely superior</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lens Fit - Corneal Coverage of Stenfilcon A and Narafilcon A Lenses</title>
        <description>Corneal coverage will be assessed for narafilcon A and stenfilcon A and categorized as extremely inadequate, slightly inadequate, optimum, slightly excessive, extremely excessive.</description>
        <time_frame>1 week</time_frame>
        <population>There were 2 participants excluded from the analysis for narafilcon A at 1 week due to protocol deviations</population>
        <group_list>
          <group group_id="O1">
            <title>Stenfilcon A</title>
            <description>Participants are randomized to wear stenfilcon A lens pair and assessed after one week during the cross over study.</description>
          </group>
          <group group_id="O2">
            <title>Narafilcon A</title>
            <description>Participants are randomized to wear narafilcon A lens pair and assessed after one week during the cross over study.</description>
          </group>
        </group_list>
        <measure>
          <title>Lens Fit - Corneal Coverage of Stenfilcon A and Narafilcon A Lenses</title>
          <description>Corneal coverage will be assessed for narafilcon A and stenfilcon A and categorized as extremely inadequate, slightly inadequate, optimum, slightly excessive, extremely excessive.</description>
          <population>There were 2 participants excluded from the analysis for narafilcon A at 1 week due to protocol deviations</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Extremely inadequate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slightly inadequate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Optimum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slighlty excessive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely excessive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lens Movement</title>
        <description>Lens movement assessed for narafilcon A and senofilcon A lenses and categorized as extremely inadequate, slightly inadequate, optimum, slightly excessive, extremely excessive.</description>
        <time_frame>1 week</time_frame>
        <population>There were 2 participants excluded from the analysis for narafilcon A at 1 week due to protocol deviations</population>
        <group_list>
          <group group_id="O1">
            <title>Stenfilcon A</title>
            <description>Participants are randomized to wear stenfilcon A lens pair and assessed after one week during the cross over study.</description>
          </group>
          <group group_id="O2">
            <title>Narafilcon A</title>
            <description>Participants are randomized to wear narafilcon A lens pair and assessed after one week during the cross over study.</description>
          </group>
        </group_list>
        <measure>
          <title>Lens Movement</title>
          <description>Lens movement assessed for narafilcon A and senofilcon A lenses and categorized as extremely inadequate, slightly inadequate, optimum, slightly excessive, extremely excessive.</description>
          <population>There were 2 participants excluded from the analysis for narafilcon A at 1 week due to protocol deviations</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Extremely inadequate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slightly inadequate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Optimum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slightly excessive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely excessive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 week</time_frame>
      <desc>Adverse events were collected during the study visit exams.</desc>
      <group_list>
        <group group_id="E1">
          <title>Stenfilcon A</title>
          <description>Participants are randomized to wear stenfilcon A as the first or second lens pair for one week during the cross over study.</description>
        </group>
        <group group_id="E2">
          <title>Narafilcon A</title>
          <description>Participants are randomized to wear narafilcon A as the first or second lens pair for one week during the cross over study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Non-ocular Non-Significant</sub_title>
                <description>Common cold</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sr. Manager Global Medical Scientific Affairs</name_or_title>
      <organization>CooperVision Inc.</organization>
      <phone>925-621-3761</phone>
      <email>javega@coopervision.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

